Navigation Links
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new Phase II data presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco. These findings are the first results from a Phase II clinical study evaluating an oral Factor Xa inhibitor in atrial fibrillation patients. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568).

The objective of the multinational study was to assess the safety of four dose regimens of DU-176b in patients with non-valvular atrial fibrillation (AF), as compared to warfarin. While the incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg twice per day), compared with warfarin, the incidence reported in the once-daily DU-176b treatment groups (30 mg or 60 mg once per day) was similar to that in the warfarin-treated patient group. Bleeding events were evaluated using guidelines established by the International Society on Thrombosis and Haemostasis(1), the most sensitive scale of those currently used in clinical studies in cardiovascular disease.

"These results are noteworthy and encouraging because we observed significantly fewer adverse bleeding events in patients receiving one dose of DU-176b per day, versus two doses per day, suggesting with this compound, the most convenient dosing regimens also appear to be safer," said Jeffrey I. Weitz, MD, FACP, FRCP, professor of medicine and biochemistry, McMaster University and director, Henderson Research Centre, Hamilton, Ontario. "These data provide insight into the optimal dosing regimens for Phase III studies of DU-176b."


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... 4, 2015 P&S Market ... overview, trends, DRO analysis, market segmentation, market size ... and top competitor profiles in: Global ... Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC on Global ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th Annual ... 3 – 4, 2015, at UC San Diego, will explore innovations that farmers ... access, and manage resources efficiently against the dueling backdrop of a lingering Western ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... Orange County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department ... stars indicate that 24/7 Care At Home’s agency is well on the path to ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... supplement manufacturing, label design, product packaging, and fulfillment services, joined over 200 other ... The event was held on Tuesday, July 28th at Jones Beach State Park ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology and security executive networking ... Lions’ Den and Jungle Lounge 2015, which will be held from 3-6:30 p.m. Aug. ... event, eight emerging security vendors, known as “Gazelles,” will go head-to-head with the ISE® ...
(Date:8/4/2015)... Washington, D.C. (PRWEB) , ... ... ... announced that its HealthCenter personal health record (PHR) product has achieved Office ... Ambulatory and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest ...
Breaking Medicine News(10 mins):Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3
... Jersey women should consider the real cost of the procedure beyond ... plastic surgeon, advises of the importance of choosing a cosmetic surgeon wisely ... , ... Paramus, NJ (PRWeb) January 27, 2009 - You may be under ...
... maintain its newsworthy coverage on its Avandia information portal with the ... side effects. The type 2 diabetes drug has been linked ... ... Denver, CO (PRWEB) January 27, 2009 -- LegalView.info, the ...
... Spectrum Software, a leading software developer for medical device makers, announced ... Technical Reports, How to Manage an FDA Controlled Software Project. ... covers best practices in software team communications, software methodologies and managing ... ...
... and founder of Secrets2MyGreatBody.com reveals how people can easily and ... and best of all, keep it off without the typical diet restrictions. ... ... of best selling weight loss program Total Body Transformation System , ...
... Medicare patients treated at top-rated hospitals nationwide across ... 27 percent less likely to die, on average, ... to a study released today by HealthGrades, the ... surgery at these high-performing hospitals also have an ...
... individual physicians and the physician partnership in litigation ... announcement that Texas Attorney General Greg Abbott has ... of the state antitrust laws.The Attorney General,s Office ... injunction prohibiting Memorial Hermann from engaging in certain ...
Cached Medicine News:Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 2Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 3Health News:Interested in Breast Augmentation, New Jersey? Be Sure You Know the “Real Cost” 4Health News:LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects 2Health News:LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects 3Health News:New Software Technology Report for Medical Device Makers: How to Manage an FDA Controlled Software Project 2Health News:Best Selling Weight Loss Expert Finally Answers The Question: Can You Achieve Permanent Fat Loss By Eating More and Exercising Less? 2Health News:Best Selling Weight Loss Expert Finally Answers The Question: Can You Achieve Permanent Fat Loss By Eating More and Exercising Less? 3Health News:Top hospitals have 27 percent lower mortality: Annual HealthGrades study 2Health News:Top hospitals have 27 percent lower mortality: Annual HealthGrades study 3Health News:Lawyers React to Texas Attorney General's Lawsuit, Settlement Against Houston's Memorial Hermann 2
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: